[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352720-105":59,"doc-detail-352720-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","engineering-of-the-melanoma-inhibitor-of-apoptosis-ml-iap-anticancer-peptide-through-comprehensive-in-silico-approaches","Engineering of the Melanoma Inhibitor of Apoptosis (ML-IAP) Anticancer Peptide Through Comprehensive In Silico Approaches","","Melanoma is a highly malignant skin cancer, with an estimated 100,000 new cases in 2022 and over 7,600 deaths in the United States alone. Anticancer peptides (ACPs) are investigated as therapeutic agents due to improved potency and biocompatibility and fewer adverse reactions. This work targets melanoma inhibitor of apoptosis (ML-IAP), modulating the conventional nonapeptide AVPIAQKSE to improve binding affinity and safety. Comprehensive in silico peptide engineering, docking, toxicity prediction, and molecular dynamics are used to evaluate engineered variants.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/engineering-of-the-melanoma-inhibitor-of-apoptosis-ml-iap-anticancer-peptide-through-comprehensive-in-silico-approaches/352720/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/engineering-of-the-melanoma-inhibitor-of-apoptosis-ml-iap-anticancer-peptide-through-comprehensive-in-silico-approaches/352720.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study on ML-IAP anticancer peptides?","Question",{"text":112,"@type":113},"To engineer the ML-IAP-targeting peptide to enhance binding affinity while improving the safety profile compared with the conventional reference nonapeptide.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were peptide variants generated and selected?",{"text":117,"@type":113},"Hotspot interface residues were identified, then saturation mutagenesis was used to explore amino-acid substitutions. Lead candidates were selected based on docking performance and predicted safety.",{"name":119,"@type":110,"acceptedAnswer":120},"Which engineered mutants showed the best overall performance?",{"text":121,"@type":113},"HVPIAQKSE, WVPWAQKSE, and HVPWAQKSE were reported as the best mutants with superior binding affinity and a favorable safety profile, supported by molecular dynamics stability over 200 ns.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352720,1790193957,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Human Mutation  \nRESEARCH ARTICLE  OPEN ACCESS   \nEngineering of the Melanoma Inhibitor of Apoptosis (MLIAP) Anticancer Peptide Through Comprehensive In Silico Approaches  \nHaitham Ahmed Al-Madhagi1 | Muhammad shahab2 , 3 | Zheng Guojun3 | Gamil Al-Madhagy4 | Mohammed Bourhia5 | Gamal A. Shazly6 | Musaab Dauelbait7 | Zunnan Huang2  \n1Biochemical Technology Program, Thamar University, Dhamar, Yemen | 2Dongguan Key Laboratory of Computer-Aided Drug Design, Guangdong Provincial Key Laboratory for Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, China | 3State Key Laboratories of Chemical Resources Engineering, Beijing University of Chemical Technology, Beijing, China | 4Department of Oral and Maxillofacial Surgery, University of Damascus, Damascus, Syria | 5Laboratory of Biology, Polydisciplinary Faculty of Safi–Cadi Ayyad University, Safi, Morocco | 6Department of Pharmaceutics, King Saud University, Riyadh, Saudi Arabia | 7Department of Scientific Translation, University of Bahri, Khartoum, Sudan  \nCorrespondence: Gamal A. Shazly ([gaahmed@ksu.edu.sa](gaahmed@ksu.edu.sa)) | Musaab Dauelbait ([musaabelnaim@gmail.com](musaabelnaim@gmail.com)) | Zunnan Huang ([zn_huang@gdmu.edu.cn](zn_huang@gdmu.edu.cn))  \nReceived: 3 December 2024 | Revised: 11 October 2025 | Accepted: 27 January 2026  \nAcademic Editor: Priya Gusain  \nKeywords: docking | MD simulation | melanoma | PCA | PPI | saturation mutagenesis  \nABSTRACT  \nBackground and Aims: Melanoma represents the most malignant type of skin cancer. It is estimated that approximately 100,000 new cases of melanoma were diagnosed in 2022, resulting in over 7600 deaths in the United States alone. Recently, anticancer peptides (ACPs) have emerged as novel therapeutic agents for cancer, offering higher potency, biocompatibility, and fewer adverse reactions in host cells. One of the druggable targets of melanoma is the melanoma inhibitor of apoptosis (ML-IAP), conventionally inhibited by the nonapeptide AVPIAQKSE. The current study is aimed at enhancing both the binding affinity and safety profile of this peptide through in silico peptide engineering.  \nMethods: Initially, the 3D structure of the protein was downloaded from the Protein Data Bank (PDB) (ID: 1OXQ) and prepared. The hotspot residues at the interface were detected using Discovery Studio Client 2021. Afterwards, saturation mutagenesis was conducted to discover the best potential amino acid substitutions with a positive impact on the binding affinity. The lead candidates were docked to the receptor via HPEPDOCK 2. Additionally, the safety profile was assessed using the ToxIBTL and AllerCatPro 2 servers. Finally, molecular dynamics simulations and principal component analysis were performed to check the stability of the best complexes.  \nResults: HVPIAQKSE, WVPWAQKSE, and HVPWAQKSE were the best mutants that could be superior to the original peptide in terms of binding affinity as well as safety profile. MD results confirmed the stability, flexibility, reduced local motions, conformational changes, and more compact structure upon binding the receptor for 200 ns, which deserve in vitro validation as abetter melanoma ACP therapeutic option.  \nConclusion: These variants displayed increased flexibility, reduced conformational alterations and local motions, and a more compact configuration, suggesting greater stability compared with the reference peptide.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nCopyright © 2026 Haitham Ahmed Al-Madhagi et al. Human Mutation published by John Wiley & Sons Ltd.  \nHuman Mutation, 2026; 2026:9356098 1 of 14  \n[https://doi.org/10.1155/humu/9356098](https://doi.org/10.1155/humu/9356098)  \n1 | Introduction  \nIt has been estimated that around 100,000 new melanoma cases were diagnosed in ","cbCaihlO7wo5dF13","https://ap.wps.com/l/cbCaihlO7wo5dF13","pdf",4207255,14,"English","# Introduction\n# Materials and Methods\n# Results\n# Discussion\n# Conclusion","[{\"question\":\"What is the main goal of this study on ML-IAP anticancer peptides?\",\"answer\":\"To engineer the ML-IAP-targeting peptide to enhance binding affinity while improving the safety profile compared with the conventional reference nonapeptide.\"},{\"question\":\"How were peptide variants generated and selected?\",\"answer\":\"Hotspot interface residues were identified, then saturation mutagenesis was used to explore amino-acid substitutions. Lead candidates were selected based on docking performance and predicted safety.\"},{\"question\":\"Which engineered mutants showed the best overall performance?\",\"answer\":\"HVPIAQKSE, WVPWAQKSE, and HVPWAQKSE were reported as the best mutants with superior binding affinity and a favorable safety profile, supported by molecular dynamics stability over 200 ns.\"}]","Engineering of the Melanoma Inhibitor of Apoptosis (ML-IAP) Anticancer Peptide Through Comprehensive In Silico Approaches | PDF",1790101111,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34a2f820b64c2911b201439121e9fd07.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59f9a0e60004fc04ad3bcbd5f2210f5d.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/291dcad092643218b886ef95f477acc4.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bee564850eddcdae84f8554fde9de98.webp",980,1287]